Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study

Franco Citterio, Gionata Spagnoletti, Maria Paola Salerno, E Favi, A Gargiulo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

6 Citazioni (Scopus)

Abstract

The half-life of everolimus is approximately 28 hours, but everolimus is generally administered twice a day. The aim of this prospective, single-center, exploratory study was to compare the efficacy and safety of a once a day everolimus (OD) with the standard twice a day administration regimen (BID) as immunosuppressive therapy in renal transplantation.
Lingua originaleEnglish
pagine (da-a)1010-1012
Numero di pagine3
RivistaTransplantation Proceedings
Volume43
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Administration, Oral
  • Antibodies, Monoclonal
  • Calcineurin
  • Chi-Square Distribution
  • Drug Administration Schedule
  • Drug Monitoring
  • Drug Therapy, Combination
  • Female
  • Graft Rejection
  • Graft Survival
  • Humans
  • Immunosuppressive Agents
  • Italy
  • Kidney Transplantation
  • Male
  • Pilot Projects
  • Prospective Studies
  • Recombinant Fusion Proteins
  • Risk Assessment
  • Risk Factors
  • Sirolimus
  • Time Factors
  • Treatment Outcome

Fingerprint Entra nei temi di ricerca di 'Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study'. Insieme formano una fingerprint unica.

Cita questo